Compare HNST & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HNST | SGHT |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.3M | 282.9M |
| IPO Year | 2021 | 2021 |
| Metric | HNST | SGHT |
|---|---|---|
| Price | $2.79 | $5.30 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $3.00 | ★ $8.23 |
| AVG Volume (30 Days) | ★ 1.6M | 197.9K |
| Earning Date | 06-01-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.65 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $371,317,000.00 | $79,866,000.00 |
| Revenue This Year | $0.17 | N/A |
| Revenue Next Year | N/A | $10.74 |
| P/E Ratio | $33.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.07 | $2.03 |
| 52 Week High | $5.62 | $9.24 |
| Indicator | HNST | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 71.34 | 35.15 |
| Support Level | $2.38 | $4.86 |
| Resistance Level | $2.98 | $5.32 |
| Average True Range (ATR) | 0.12 | 0.32 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 94.12 | 22.69 |
The Honest Co Inc is a digitally-native consumer products company to makes purpose-driven consumer products designed for all people. It is an omnichannel brand, ensuring its products are available wherever its consumers shop through the company's Retail and Digital channels. It has three product categories namely; Diapers and Wipes, Skin and Personal Care, and Household and Wellness, out of which the majority of its revenue is generated from the sale of diapers and wipes. The company operates only in the United States.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.